To create a human therapeutic vaccine able to circumvent self-tolerance against tumor necrosis factor (TNF) ␣, foreign T helper epitopes were inserted into human TNF␣, with minimal effect on the native three-dimensional structure. TNF␣ variants were screened for solubility, structural stability, biological activity, and after immunization, for eliciting inhibitory antibodies. The longest and most flexible loop in TNF␣, also designated loop 3, is the only region that is not involved in intra-or intermolecular interactions and therefore constitute an attractive insertion site. However, the extension of the flexible loop by epitope insertions destabilized the TNF␣ molecule. Therefore, two cysteines were introduced to form a stabilizing disulfide bond between loops 2 and 3. In a second design approach, three TNF␣ monomers were linked by two T cell epitopes and expressed as a single chain TNF␣ trimer. TNF␣ variants that were expressed as soluble proteins also had a conserved tertiary structure, as determined by circular dichroism. The biological activity of the TNF␣ variants was of the same magnitude as human TNF␣ in cellular assays. Introduction of three separate single-point mutations (D143N, A145R, or Y87S) diminished the cytotoxicity of the mutated variants 50 -800-fold compared with native TNF␣. Antisera from mice immunized with the different TNF␣ variants were able to cross-react with native human TNF␣ and to inhibit TNF␣ signaling via the TNF receptors in vitro, suggesting that the structural binding epitopes of native human TNF␣ and thus the native conformation were conserved in the constructed vaccine candidates.
Tumor necrosis factor ␣ (TNF␣)
1 is a pleiotropic cytokine, which plays a central role in immune regulation and as an inflammatory and host defense mediator (1) . The multiple biological effects of TNF␣ are mediated both through binding of membrane-bound and soluble TNF␣ to two cell surface TNF receptors TNFRI and TNFRII, each displaying diverse kinetics of activation upon binding of TNF␣ (2) . The successful use of TNF␣ antagonists in relieving pain and symptoms in patients suffering from rheumatoid arthritis and Crohn's disease has confirmed the important role of TNF␣ in inflammatory diseases. At present, the anti-TNF␣ monoclonal antibodies Infliximab (3) and Adalimumab (4) , as well as the soluble TNF receptor Etanercept (5), have been approved for clinical use as TNF␣ antagonists. In addition, several alternative anti-TNF␣ treatments, such as intracellular kinase inhibitors, TNF␣ synthesis inhibitors, TNF␣ membrane-release inhibitors, as well as other soluble TNF␣ blockers are under development (6) .
Another potential strategy to target overexpression of TNF␣ is the induction of antibody responses against TNF␣ in the patient through immunization or active immunotherapy. However, one obstacle in the development of such a vaccine is that immunological T cell tolerance against TNF␣ needs to be circumvented to induce a sufficiently strong immune response with the capacity to neutralize endogenous TNF␣. By the use of the AutoVac TM technology, where a foreign immunodominant T helper cell epitope is inserted into the native self-protein, T cell tolerance to the self-protein can be circumvented (7) . Furthermore, the activation of hetero-reactive T cells leads to an induction of T cell-dependent polyclonal antibody production, which has the ability to cross-react with and neutralize the endogenous target protein. Most importantly, immunization with a modified self-protein, containing a foreign and immunodominant T cell epitope, allows for the immune response to be driven by hetero-reactive, rather than auto-reactive, T cells and re-immunization is a prerequisite to maintain high levels of neutralizing antibodies. Clearly, the development of a therapeutic and safe vaccine against TNF␣ would be preferable to the use of monoclonal anti-TNF␣ antibodies or engineered TNF receptors with respect to the amount of protein needed for each treatment and the convenience of the patients.
The aim of the current investigation was to develop a modified human TNF␣ protein that, upon immunization, would induce the activation of T cells specific for the modified protein and the generation of an antibody response that could crossreact and neutralize native human TNF␣. However, to be able to induce a polyclonal B cell response with high cross-reactivity to the wild type protein, it was of pivotal importance to insert the foreign immunodominant T cell epitope into the native TNF␣ sequence in such a way that the structural identity and, consequentially, conformational B cell epitopes between the modified protein and wild-type human TNF␣ were maintained. Introduction of foreign epitopes in a trimeric protein, like TNF␣, without interfering with the native conformation is not trivial. Active TNF␣ consists of three homologous monomers that self-associate into a symmetrical non-covalent trimer with a molecular weight of 52,000 (8) . The individual 157-amino acid monomer consists of anti-parallel ␤-sheets organized into a jellyroll-like structure (9) with an intra-molecular disulfide bond between residues Cys 69 and Cys 101 . By circular dichroism, it has been shown that the trimeric structure unfolds at 60°C where ␣-helical structures are introduced in the monomer (9) . Furthermore, more than half the amino acids in TNF␣ have been investigated through different point mutations by various researchers (10) . Most of the point mutations resulted in decreased stability, solubility, and/or trimer formation leading to low expression yields and the formation of inclusion bodies when expressed in Escherichia coli. The subsequent refolding required for the formation of trimeric proteins is at best a cumbersome process, mainly because of the hydrophobic interactions that stabilize a correctly folded molecule. To avoid the generation of inclusion bodies and to maintain the biophysical characteristics of native human TNF␣, we have investigated several different strategies. These include the identification of a flexible loop where the foreign T cell epitope could be inserted with negligible effect on the intra-or intermolecular interactions of the trimer protein, and expression of a single chain TNF␣ trimer with the T cell epitopes inserted as linkers between the monomers.
EXPERIMENTAL PROCEDURES

Construction of TNF␣ AutoVac
TM Variants from Synthetic GenesSynthetic genes encoding either a TNF␣ monomer or a single chain TNF␣ trimer were designed by codon optimization of the TNF␣ gene for E. coli expression, according to the codon usage data base. Codons with a frequency in E. coli of less than 10% were excluded. The genes were obtained as sequenced clones from GeneArt GMBH, in the case of the TNF␣ monomer as a single clone, and in the case of the trimer, as three colony PCR products each representing one of the three embedded TNF␣ genes. Codon usage was modified to create three TNF␣ monomers with identical amino acid sequences but with distinct cDNA sequences, for the single chain TNF␣ trimer (TNF_T) gene. This was done to circumvent PCR recognition problems upon assembly of the monomers. The three PCR products were cloned using the TOPO system (Invitrogen), into the pCR2.1-TOPO vector. These clones were then used as templates in three separate PCR to generate fragments that were assembled by SOE PCR (11) . Briefly, two fragments were assembled to generate a dimeric TNF␣ gene, which subsequently was used as template to assemble the final single chain TNF␣ trimeric gene. The assembled gene was cloned into the pET28bϩ vector and transformed into competent HMS174 E. coli cells. A sequence verified clone was isolated and used as template for the generation of the single chain TNF␣ trimer constructs. The TNF␣ monomeric cDNA was moved from the pCR-Script vector to the pET28bϩ vector, and used as template for the generation of flexible loop constructs.
Insertion of Epitopes-The artificial T cell Pan DR epitope named PADRE (sequence AKFVAAWTLKAAA) (12) was inserted into the flexible loop variants and the tetanus toxoid epitopes P2 and P30 (sequence QYIKANSKFIGITEL, and sequence FNNFTVSFWLRVPKVSASHLE) into the single chain TNF␣ trimer by the SOE PCR technique, to generate TNF␣ AutoVac TM variants. All variants were sequence verified and transformed into the E. coli strain HMS174(DE3).
TNF␣ AutoVac TM Expression-All proteins were expressed in HMS174 cells in defined media (13) . Different combinations of temperature (37 and 25°C) and isopropyl-1-thio-␤-D-galactopyranoside were tested for optimal expression.
Purification of TNF␣ Variants-Purification of the flexible loop TNF␣ variants was based on a combination of Bio-Gel hydroxyapatite HTP (Bio-Rad) and Q-Sepharose anion exchange chromatography (Amersham Biosciences) (14) with minor modifications.
The single chain TNF␣ trimer variants were purified to apparent homogeneity by monoclonal antibody affinity chromatography. The monoclonal antibody Infliximab (3) was coupled to CNBr-activated Sepharose CL-4B (Amersham Biosciences). After capture, the single chain TNF␣ trimers were eluted with 100 mM glycine, 500 mM NaCl, pH 11. Fractions were collected, pooled, and transferred directly to dialysis against 20 mM Tris-HCl, 150 mM NaCl, pH 7.0.
MALDI-TOF Mass Spectrometry-Mass spectrometric analysis was performed using Autoflex equipment (BRUKER Daltonik, Germany). Sinapinic acid was used as matrix with samples of TNF␣ variants previously desalted and concentrated using ZipTip HPL (MilliPore, Denmark). Trypsin digestion (Promega) of TNF␣ variants were performed in 20 mM Tris-HCl, 150 mM NaCl, pH 8.0, using sequence grade trypsin by incubation for 20 h at room temperature. Peptides were mixed directly (1:1) with a saturated solution of ␣-cyano-4-Hydroxycinnamic acid in 33% acetonitrile (v/v), 0.1% trifluoroacetic acid (v/v) followed by application onto an AnchorChip target plate. The analysis was carried out in linear mode.
Circular Dichroism Analysis-Circular dichroism measurements were carried out on a JASCO J-715 spectropolarimeter instrument (Gross-Umstadt, Germany) with quartz cells of 1-mm path length. Proteins were examined at a concentration of 0.5-1.0 mg/ml in 20 mM Tris-HCl, 150 mM NaCl, pH 7.5. The thermal denaturation was followed by scans from 280 to 200 nm at temperatures ranging from 25 to 85°C.
N-terminal Sequencing-N-terminal sequencing of variants were routinely done on a model 476A Protein Sequencer (Applied Biosystems). ProSorb cartridges (PerkinElmer Life Sciences) were used for desalting samples prior to the analysis.
Measurement of Direct Binding to TNFRI and TNFRII-Polystyrene microtiter plates (Maxisorp, Nunc A/S, Denmark) were coated overnight with 50 ng/ml TNFR (I or II; R&D Systems), respectively, in a coating buffer (0.1 M Na 2 CO 3 , pH 9.5). After blocking with an ELISA buffer (10 mg/ml bovine serum albumin and 0.0005% phenol red in phosphate-buffered saline, pH 7.2), the plates were washed with a washing buffer (phosphate-buffered saline containing 0.5 M NaCl and 1% Triton X-100, pH 7.5). The investigated TNF␣ variant was applied to the microtiter plate in serial dilutions in the ELISA buffer and incubated for 1 h at 20°C. The plates were subsequently washed and bound TNF␣ variants were detected by applying biotinylated goat antihuman TNF␣ (BAF210, R&D Systems), diluted to 0.5 g/ml in the ELISA buffer, and incubated for 1 h. After washing, the plates were incubated for 1 h with streptavidin-conjugated horseradish peroxidase (RPN1231V, Amersham Biosciences) diluted 1:1000 in the ELISA buffer, washed, and developed with o-phenylenediamine dihydrochloride (Sigma P-8287) (1 mg/ml) dissolved in citrate phosphate buffer, pH 5, and H 2 O 2 (0.03%). The plates were read on an Elx 808 ELISA reader (Bio-Tek Instruments, Burlington, VT) at 490 nm, using 620 nm as reference.
Quantitative TNF␣ ELISA-7.0 g/ml rabbit anti-goat antibodies were coated overnight in coating buffer. Goat anti-human TNF␣ in the ELISA buffer was incubated for 1 h and subsequently washed. TNF␣ variants and human TNF␣ (R&D Systems) as standard were applied to the microtiter plate in serial dilutions in the ELISA buffer and incubated for 1 h at 20°C. After washing, detection was made as described for the receptor ELISA. The concentrations of the variants were calculated by interpolation to the TNF␣ standard fitted to a four-parameter plot using KC4 software (Bio-Tec Instruments).
Immunizations-Groups of 10 Balb/C female mice (Taconic M&B, Denmark) were immunized subcutaneously with 50 g of protein emulsified in Complete Freund's adjuvant (Sigma). Two, 6, and 10 weeks later, mice were boosted with 25 g of protein in incomplete Freund's adjuvant (Sigma). One week after each boost (i.e. 3, 7, and 11 weeks after the first immunization), blood samples were collected and serum was prepared. Sera were stored at Ϫ20°C until analyzed. All mice were between 7 and 12 weeks of age, at the start of the experiments. All experimental procedures had been approved by the Danish Animal Experimentation Inspectorate.
Cell Line-The KYM-1D4 (KD4) cell line derived from human rhabdomyosarcoma cells was kindly provided from A. Meager (Division of Immunology, National Institute of Biological Standards and Controls). Culturing of cells was essentially performed as described previously (15) .
Cell Culture Assays-For neutralization assays, KD4 cells were cultured in triplicates in microtiter plates at 2 ϫ 10 4 cells/well in the presence of a constant concentration of in-house produced human wild type TNF␣ (100 pg/ml a concentration inducing at least half-maximum cellular death) and titrated amounts of mouse sera. In addition, pooled control serum from mice, which had received 3-4 immunizations with an irrelevant protein (KLH) in Complete Freund's adjuvant/incomplete Freund's adjuvant, was used as a negative control in the neutralization assay. For cytotoxicity assays, cells were cultured as above in the presence of titrated amounts of human TNF␣ or TNF␣ AutoVac TM variants. After 48 h of incubation, cell survival was determined by MTS, inner salt (CellTiter 96® AQ ueous 1 Solution Cell Proliferation Assay, Promega). In the neutralization assay, relative cell viability was calculated by dividing the mean optical density value from wells with cells cultured in the presence of TNF␣ and sera with the mean optical density value from wells where cells had been cultured in the absence of both protein and sera. The IC 50 value, corresponding to the amount of sera resulting in 50% inhibition of TNF-mediated cell cytotoxicity, was determined by interpolating the OD 50 value onto the x axis (Y50 ϭ
where Y max is the relative cell viability of cells cultured in the absence of sera and TNF␣ (i.e. 100%) and Y min is the maximum relative cell viability observed for cells cultured in the presence of TNF␣ and titrated amounts of sera from control immunized mice). In the cytotoxicity assay, relative cell viability was calculated by dividing the mean optical density value of cells cultured in the presence of TNF␣ variants with the mean optical density value of cells cultured in the absence of TNF␣. An ED 50 value, corresponding to the concentration of TNF␣ inducing half-maximum cytotoxicity, was calculated as described for the IC 50 value (i.e. Y50 ϭ (Y max Ϫ Y min )/2 ϩ Y min , where Y max is the relative cell viability of cells cultured in the absence of TNF␣ (i.e. 100%) and Y min is the minimal OD value obtained from cells cultured in the presence of TNF␣ variants).
RESULTS
Design of Flexible Loop
Variants-The purpose of this work was to insert a foreign T cell epitope into the native TNF␣ molecule to create stable and soluble TNF␣ AutoVac TM variants. The crystal structure of TNF␣ bound to its receptor has not been published. However, from the structure of the TNF␣ family member TRAIL bound to the DR5 receptor, it is expected that the three major receptor interacting sites of the TNF␣ molecules are located along the edge of TNF␣ (16) . To create TNF␣ AutoVac TM variants that could induce a polyclonal antibody response that was directed to receptor binding epitopes and thereby able to inhibit TNF␣ activity, the T cell epitope insertions were not performed in the proposed receptor binding regions.
Prior to this work, we constructed numerous variants where, e.g. parts of ␤-strands of TNF␣ had been substituted with foreign T cell epitopes. However, this strategy resulted in expression as inclusion bodies in E. coli. This is in contrast to native human TNF␣ that is readily expressed as a soluble protein in E. coli (17) . Consequently, we used another approach to find permissive sites for epitope insertions within regions of TNF␣ that would not affect the conformation of the core TNF␣ molecule. This was done by identification of flexible regions from crystal structures of TNF␣, together with information from superimposition of human and murine TNF␣ structures and sequence alignment of TNF␣ from different species. In this way loop 3 (Arg 103 -Lys 112 ) was identified as a potential site for insertion of epitopes.
The PADRE epitope was inserted at several positions in flexible loop 3 by direct insertion and/or with deletion of one or more amino acids in TNF␣ (Fig. 1) . The resulting variants were analyzed for soluble expression in E. coli. Interestingly, only variants where the T cell epitope had been inserted C-terminal (e.g. TNF4, TNF7, and TNF8) and not N-terminal of Gly 108 were expressed as soluble proteins.
The stability of proteins can be increased by insertion of cysteines that form disulfide bonds (18) . We therefore designed another TNF␣ variant, TNF4A, containing an extra disulfide bond, to examine if this would have a beneficial effect on the variant stability. Stabilization of the TNF4A variant was done by introduction of a new disulfide bond opposite the native disulfide bond, connecting the flexible loop 3 to the non-flexible loop 2 (Lys 65 -Val 74 ). Thereby, the inserted PADRE peptide became positioned between two disulfide bonds both connecting loops 3 to 2 (Fig. 2) . To achieve this the crystal structure of TNF␣ was analyzed, and Gln 67 and Ala 111 were selected for substitution with cysteines. The distance between the C␣ atoms of these residues is 5.2 Å, approximately the same distance as between the residues harboring the native disulfide bond (Cys 69 and Cys 101 ; 5.7 Å). As for TNF4 (without the extra disulfide bond), TNF4A was also successfully expressed as a soluble protein in E. coli (Fig. 1) . A schematic view of the structure of the flexible loop variants with and without the introduced disulfide bond is seen in Fig. 3, A and B . The highest expression levels (200 mg/liter) of soluble flexible loop variants, as determined by ELISA, were observed when cultured at 25°C, both pre-and post-induction.
Design of Single Chain TNF␣ Trimer-As an alternative approach to produce stable TNF␣ variants, single chain TNF␣ trimer variants were designed. cDNA of three TNF␣ monomers were linked by glycine linkers and two tetanus toxoid-derived T cell epitopes, P2 and P30, were placed in the linker regions.
From the crystal structure of native trimeric TNF␣ it was perceived that the C-terminal Leu 157 is located at the entrance . In TNF7 Ala 109 was deleted from the TNF␣ sequence. In TNF8 amino acids 109 to 111 were deleted and in TNF9 amino acids 107 to 111 were deleted, respectively, by the insertion. The ϩ denotes soluble expression and Ϫ denotes lack of soluble expression. of the interface region of the three monomers, where they make important salt bridges to Lys 11 in the successive monomer (8) . The distance between the C␣ atom of residue Leu 157 to the C␣ of Arg 6 of the next monomer (the first five residues are not determined in the crystal structure) is only 12-15 Å. To minimize the disruptive forces on Leu 157 , glycine linkers (GGG) of approximately 10 Å length were introduced between the epitopes and the TNF␣ monomers. A schematic overview of the structure is seen in Fig. 3C . Optimal growth conditions were found to be the same as for the flexible loop variants, i.e. 25°C, both pre-and postinduction. However, protein expression levels were lower for the single chain TNF␣ trimers with an approximate expression of 20 mg/liters.
Characterization of Purified Variants-After purification, the N-terminal sequences were determined and found to be identical to the TNF␣ sequence. The molecular masses, as determined by MALDI-TOF, correlated with the theoretical values within 1 or 2 daltons. Reduced SDS-PAGE analysis revealed that the purity was about 90% for all the variants. Under certain expression conditions, 5-10% of the flexible loop constructs were degraded. The single chain TNF␣ trimer (TNF_T) was expressed as a protein with a molecular weight corresponding to a trimer, but breakdown products corresponding to dimeric and monomeric bands were also detected in Western blots (data not shown). Non-reduced Coomassiestained SDS-PAGE demonstrated that the flexible loop variants migrated as monomeric TNF␣. In the same analysis, the variant containing the introduced cysteines (TNF4A) also migrated as a monomer, indicating that the intramolecular disulfide bonds were correctly formed. Flexible loop variants were tested for solubility at high concentrations and were readily soluble at concentrations ranging from 0.75 to 50 mg/ml in 150 mM sodium phosphate buffer, pH 7.0, without significant precipitation. Far-UV spectra equivalent to human TNF␣ were obtained by circular dichroism analyses. All examined variants had a characteristic minimum at 220 nm, indicating a predominantly ␤-stranded protein structure (data not shown).
Stability of the TNF␣ variants was analyzed by near-UV circular dichroism during heat-induced denaturation. Denaturation temperatures were above 40°C for the single chain TNF␣ trimer, ϳ50°C for the monomer variants, and ϳ65°C for the variant that was stabilized by introduction of a new disulfide bond (see Fig. 4 ). As expected, native human TNF␣ denatured at 60°C (9) .
The correct formation of the two disulfide bonds in TNF4A was confirmed by MALDI-TOF analyses on non-reduced and reduced trypsin-digested samples. Under non-reduced conditions a peak of 4,955.18 daltons was identified. This peak consists of a tripeptide held together by the two introduced cysteines and the two naturally occurring cysteines (Fig. 5A) . After reduction of the trypsin-digested TNF4A, the tripeptide complex disappeared and a new peak of 2,583.81 daltons appeared. This peak has a mass analogous to the Ala 119 -Lys 141 peptide representing the longest cysteine containing peptide (Fig. 5B) . The second cysteine containing peptide Gly 66 -Arg 82 was detected as a weaker peak at 1779.28 daltons. The third peptide was too short to be identified in this assay. Further evidence of the stabilizing effect of the introduced disulfide bond was done by a comparison of reduced and nonreduced SDS-PAGE that included purified TNF4A with partial cleavage in the PADRE region. Two degradation products, resulting from PADRE cleavage, were seen in reduced gels at 12 and 6 kDa, below the 18-kDa intact monomer band. Because TNF4A migrates as a single monomeric band at 18 kDa in non-reduced SDS-PAGE, the introduced disulfide bond must link the two degradation fragments together (data not shown). All variants eluted analogous to the human TNF␣ in size exclusion chromatography analyses corresponding to a theoretical TNF␣ trimer weight of 52,000 for the variants (results not shown).
Biological Activity of TNF␣ Variants and Design of Partially Inactivated
Variants-TNF␣ has toxic activity when injected into animals (19) and humans (20) . Interestingly, both the flexible loop and single chain TNF␣ trimer variants exhibited cytotoxicity comparable with the wild type TNF␣ in a cell based assay (Fig. 6A) . FIG. 4 . Near-UV circular dichroism analysis during heat denaturation of TNF4 and TNF4A. The influence of introduction of an extra disulfide bond on protein stability. Enhanced stability was observed for TNF4A (black), which displayed structural changes at 65°C compared with TNF4 (gray) where denaturation begins already at 50°C.
FIG. 3. Design of TNF␣ AutoVac
TM variants. Two different strategies were used for design of TNF␣ variants. In the flexible loop variants, the PADRE epitope was inserted into the TNF␣ sequence with or without deletions (A). A stabilizing disulfide bridge was introduced (B), and in the single chain TNF␣ trimer approach the epitopes were inserted between the monomers (C). Blue, TNF␣ wild-type sequence; red, PADRE; black lines, disulfide bond; purple, P2; and pink, P30.
TNF4A was even 3-5-fold more toxic than human TNF␣. The cytotoxicity of the TNF␣ variants is suggestive of a native-like conformation. A strong toxicity is, however, not desirable in a vaccine. Consequently, to reduce the cytotoxicity of the TNF␣ AutoVac TM molecules, three different point mutations known to significantly reduce the toxicity of TNF␣ were introduced into the variants: D143N, A145R (21), and Y87S (22) . Variants containing either of these mutations were constructed, expressed, purified as described for the other variants, and the cytotoxicity of the point-mutated variants was analyzed in the cellular assay. The point mutations decreased the toxicity of the flexible loop variants. Neither TNF7-Y87S nor TNF4-A145R had any measurable cytotoxic activity, even at a concentration as high as 250 ng/ml (Fig. 6A) . The single chain TNF␣ trimer, with just a single point mutation (TNF_T-1xA145R), still exhibited strong cytotoxicity, indicating that a single point mutation per single chain TNF␣ trimer was not sufficient to decrease the biological activity (Fig. 6B) . However, the single chain TNF␣ trimer (TNF_T-3xA145R), with a point mutation in each monomer sequence, had no measurable cytotoxicity even at the highest concentration tested (250 ng/ml) and therefore was at least 800-fold less toxic than the commercially available TNF␣. Before introduction of the detoxifying point mutations, all variants could bind to TNFRI and TNFRII in comparable amounts to human TNF␣. The relative receptor binding of the detoxified variants compared with the active parent proteins are described in Table I . According to the literature, two of the mutations, D143N and A145R, should specifically decrease binding to TNFRI (21) , whereas Y87S should decrease the reactivity both toward TNFRI and TNFRII (22) . Indeed, all variants containing one of the three point mutations displayed significantly reduced binding to TNFRI, but only the variant containing the Y87S mutation also displayed significantly reduced binding to TNFRII. A145R variants had less than a 2-fold change in TNFRII binding, indicating only a minor change in K d for TNFRII binding after introduction of the A145R mutation. The D143N mutation resulted in a less stable protein, which had 4-fold lower soluble expression levels and the variant precipitated upon storage at Ϫ20°C. The A145R and Y87S mutations did not change the soluble expression levels or the storage stability of the parent protein.
Induction of Neutralizing Antibodies in Mice-To determine the ability of the TNF␣ variants to induce neutralizing antibodies, mice were immunized with each of the purified human TNF␣ variants and the antisera were analyzed for cross-reactivity and neutralization of human wild-type TNF␣ in the cytotoxicity assay (Fig. 7A) . Antisera from mice immunized with the different variants could cross-react with human wildtype TNF␣ and neutralize its biological activity in vitro. In fact, serum concentrations as low as 0.01-0.03% (corresponding to a serum dilution of 10,000 -30,000) were sufficient to achieve 50% inhibition of TNF␣-mediated cytotoxicity in KD4 cells (Fig. 7B) . DISCUSSION TNF␣ has attracted significant interest because of the important and multiple biological functions of the protein. The expression and correct folding of the molecule is dependent on the formation of ␤-strands in the TNF␣ monomer and the hydrophobic interactions between the monomers that are involved in trimer stability. Consequently, it is not surprising that most mutations in structurally important regions of TNF␣ result in low expression and unspecific aggregation (17) . Obtaining a stable TNF␣ vaccine candidate containing peptide insertions is therefore not trivial and most insertions resulted in aggregation and inclusion body formation. As mentioned above, numerous different strategies for insertion of foreign T cell epitopes were evaluated prior to this work. The present report describes in detail the evident structural sensitivity of TNF␣ to insertion of short peptide epitopes, where a shift of the peptide insertion site by as little as one or two amino acid residues decreased the expression levels of soluble protein from 200 to below 10 mg/liter (Fig. 1) . A permissive site for insertion of epitopes in the flexible loop 3 region of human TNF␣ was identified and used for construction of variants that were successfully expressed as soluble proteins and had biophysical and biological properties corresponding to native human TNF␣.
Experiments with stabilization of T4 lysozyme have shown that introduction of disulfide bonds between flexible domains may result in an increase of heat stability by as much as ϩ11°C (18) . The number of disulfide bonds in the TNF␣ cytokine family varies: human TNF␣ and Tweak have one disulfide bond each, but at different locations, whereas TRAIL has only an unpaired cysteine and lymphotoxin ␣ has no cysteines at all (23) . None of these proteins have cysteines at the positions used in the present investigation for introduction of a stabilizing disulfide bond. In the flexible loop variants, introduction of the PADRE epitope decreased the heat stability by 10 to 50°C. However, introduction of an extra disulfide bond improved the heat stability to 65°C, which is 5 and 15°C higher than the denaturation temperature of human TNF␣ and the paternal TNF4 variant, respectively.
Yet another novel approach of epitope insertions into a multimeric protein was made by the construction of single chain TNF␣ trimer molecules, where three TNF␣ monomers were linked together via the inserted epitopes and glycine linkers. However, the single chain TNF␣ trimer variants were not as temperature stable as the flexible loop variants and the expression levels were only about 10% of that of the flexible loop variants. The single chain TNF␣ trimer variants did, however, retain a high cytotoxic activity and were able to induce neutralizing antibodies, indicating that the single chain TNF␣ values, corresponding to the protein concentration inducing half-maximum cellular toxicity, of 12 experiments with commercial (huTNF(com)) and in-house produced TNF␣ (huTNF(ih)) and four experiments with TNF␣ variants. It should be noted that although bars for TNF7-Y87S, TNF7-A145R, or single chain TNF␣ trimer-3xA145R indicate an ED 50 value of 250 ng/ml, an exact ED 50 value was not obtained, as the highest protein concentration tested (250 ng/ml) did not induce significant cytotoxicity (see B). B, cell viability of KD4 cells cultured in the presence of titrated amounts of huTNF and the single chain TNF␣ trimer 1xA145R, containing one mutation or the single chain TNF␣ trimer (TNF_T-3xA145R), containing three mutations; one per monomer.
trimer folds into a conformation resembling the native structure of TNF␣.
The native human TNF␣ trimer normally exists in equilibrium between the trimeric and monomeric forms, and dissociation of trimeric TNF␣ correlates with decreased protein concentration, which is also influenced by pH (24) . Furthermore, the monomeric form of human TNF␣ binds poorly to the receptor in vitro (25) . Compared with native human TNF␣, an enhanced cytotoxicity of both the single chain TNF␣ trimer and the disulfide bond stabilized variant at low protein concentrations (pg/ml scale) was observed. This may well be expected by the higher trimer-tomonomer ratios at low protein concentrations for these variants, compared with the native TNF␣ molecule.
It is noteworthy that the extension of the flexible loop, generated by the epitope insertions, did not influence the ability of the flexible loop variants to bind to the TNF receptors. Even though loop 3 points into the receptor and potentially could cause steric hindrance, the loop is not directly involved in the receptor-binding site (26) .
Administration of native TNF in humans is associated with dose-related toxicity, ranging from local inflammation and headache to severe hypotension (27) . Consequently, unacceptable toxicity by local administration of an expected dose of 100 -500 g of a TNF␣ AutoVac TM vaccine cannot be excluded and therefore needs to be considered. To circumvent any foreseeable adverse reactions, the toxicity of TNF␣ AutoVac™ was significantly reduced by means of three different single point mutations. Both A145R and Y87S variants are interesting vaccine candidates, as neither soluble expression, nor protein stability, was affected by these mutations, whereas the toxicity of the molecules was reduced by up to 800-fold, which is comparable with reported observations (21, 22) .
When the AutoVac TM technology is employed to create therapeutic vaccines able to bypass self-tolerance to the target protein, various T cell epitopes can be used to provide a T helper response. In this work, we have used the P2 and P30 epitopes (28) , which are derived from tetanus toxoid in the single chain TNF␣ trimer variant. Both P2 and P30 are socalled promiscuous T cell epitopes that are used to create vaccines that are immunogenic for the majority of MHC haplotypes in the human population. However, the P2 and P30 peptides together consist of 35 amino acids and it would be difficult to insert both of these epitopes in a structurally sensitive protein like TNF␣. Therefore, the synthetic T cell epitope PADRE of 13 amino acid residues (12) was used in the flexible loop variants.
All variants used for immunizations in mice were able to elicit antisera that could recognize and neutralize native human TNF␣. In a similar immunization experiment in monkeys, using one of the flexible loop TNF␣ variants formulated in Alhydrogel, neutralizing antibodies were also obtained. 2 The results from the monkey study and the results described in this paper all support the idea that immunization with TNF␣ AutoVac TM can lead to an anti-TNF␣ antibody response and neutralization of TNF␣ signaling and therefore could constitute a valuable addition to current anti-TNF␣ directed therapies. There are several potential benefits by using an AutoVac TM approach to down-regulate TNF␣ activity over existing TNF␣ antagonists. All the anti-TNF␣ immunotherapies on the market have reported the occurrence of anti-product antibody responses (29) and even Adalimumab, a fully humanized monoclonal antibody, elicited anti-product antibodies in 5% of the patients (30). In addition, the approved TNF␣ antagonists are administered by injection or infusion of up to hundreds of milligrams of anti-TNF␣ agent, whereas TNF␣ Au- a Purified variants were compared in the TNF receptor ELISA at the same concentrations. The binding of the active and not mutated TNF␣ variants were set to 100% and compared with the residual binding of the single point mutated variants. Data from three experiments are shown as mean Ϯ S.D.
b ND, not determined. c The single chain TNF␣ trimer (TNF_T) without detoxifying mutations TNF_T was not used in this experiment. Instead, TNF_T-1xA145R was used and compared with the fully detoxified TNF_T-3xA145R molecule. However, in a separate experiment, TNF_T-1xA145R was found to display comparable binding to TNFRI and TNFRII as TNF_T and native TNF␣ (i.e. 100%; data not shown). toVac TM is expected to be injected in microgram amounts. The relatively small amount of protein needed for the TNF␣ AutoVac TM vaccine also constitutes an advantage in terms of production volumes.
